NCT01697007View on ClinicalTrials.gov

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2015

Conditions
VaccinesHIVSafetyImmunogenicity
Interventions
BIOLOGICAL

HIVIS DNA vaccine

DEVICE

Zetajet

DEVICE

Derma Vax Electroporation

BIOLOGICAL

Modified Vaccinia Ankara (MVA-CDMR)

Trial Locations (3)

Unknown

Instituto Nacional de Saude, Maputo

Muhimbili University of Health and Allied Sciences, Dar es Salaam

Mbeya Medical Research Programme, Mbeya

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Swedish Institute for Infectious Disease Control

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

US Military HIV Research Program

NETWORK

collaborator

Medical Research Council

OTHER_GOV

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

Imperial College London

OTHER

collaborator

Mbeya medical research program

UNKNOWN

collaborator

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

lead

Muhimbili University of Health and Allied Sciences

OTHER